BioCentury | Jan 5, 2021
Finance

Immuneering, Terns, Ikena raise crossover rounds as IPO queue stands to grow again

...a Phase IIa trial of FXR agonist TERN-101...
BioCentury | Jan 17, 2019
Company News

Management tracks: eGenesis names Sekhri CEO

...research at Gilead. This year, Terns plans to begin Phase I testing of lead product TERN-101 (LY2562175)...
BioCentury | Nov 2, 2018
Financial News

NASH company Terns raises $80M series B

...Asia Ventures. Terns has exclusive, worldwide rights to develop and commercialize its lead NASH compounds, TERN-101...
...TERN-101 in China and TERN-201 in China and the U.S. to treat NASH. He said TERN-101...
...series B funds to last until mid to late 2020 and enable Terns to develop TERN-101...
BioCentury | Nov 1, 2018
Finance

OrbiMed’s NASH Terns

...attracted by the cross-border organization of Terns.” Carl Gordon, OrbiMed The assets from Lilly are TERN-101 (LY2562175)...
...an undisclosed target. In 1H19, Terns plans to start a Chinese Phase I trial of TERN-101...
...enter the clinic by 2020, and the company plans to develop them in combination with TERN-101...
BioCentury | Oct 30, 2018
Financial News

NASH company Terns raises $80M series B

...Asia Ventures. Terns has exclusive, worldwide rights to develop and commercialize its lead NASH compounds, TERN-101...
...TERN-101 in China and TERN-201 in China and the U.S. to treat NASH. He said TERN-101...
...series B funds to last until mid to late 2020 and enable Terns to develop TERN-101...
BioCentury | Apr 6, 2018
Company News

Terns acquires NASH compounds from Eli Lilly

...disclose financial terms. Terns will initially focus on developing the candidates in China. Terns gains TERN-101 (LY2562175)...
BioCentury | Apr 4, 2018
Company News

Terns acquires NASH compounds from Eli Lilly

...disclose financial terms. Terns will initially focus on developing the candidates in China. Terns gains TERN-101 (LY2562175)...
Items per page:
1 - 7 of 7